Re: Scott A. Tomlins, John R. Day, Robert J. Lonigro, et al. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.04.039
- PMID: 26215600
- DOI: 10.1016/j.eururo.2015.07.028
Re: Scott A. Tomlins, John R. Day, Robert J. Lonigro, et al. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.04.039
Comment in
-
Reply to Carsten Stephan, Henning Cammann, and Klaus Jung's Letter to the Editor re: Scott A. Tomlins, John R. Day, Robert J. Lonigro, et al. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.04.039.Eur Urol. 2015 Nov;68(5):e108. doi: 10.1016/j.eururo.2015.07.027. Epub 2015 Aug 1. Eur Urol. 2015. PMID: 26242717 No abstract available.
Comment on
-
Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.Eur Urol. 2016 Jul;70(1):45-53. doi: 10.1016/j.eururo.2015.04.039. Epub 2015 May 16. Eur Urol. 2016. PMID: 25985884 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
